Effect of buprenorphine on the treatment of psychosis in bipolar patients with psychotic symptoms

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190905044703N1

Enrollment

Registered

2019-10-05

Start date

2019-10-12

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis. Other stimulant related disorders

Interventions

Intervention 1: Intervention group: Intervention group: Intervention group, sublingual buprenorphine 1 to 2 mg as needed, clonazepam 1 or 2 mg as needed, three gabapentin 300 mg daily, clonidine 0.2 h

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 18 to 65 Diagnosis of type 1 BMD (Depression episode, Mania with Psychotic Leader) (based on DSM-V criteria) Initial Severity of Positive Symptoms: BPRS psychotic score with a score of 12 or greater and at least two BPRS psychotic items with a score of 4 or more

Exclusion criteria

Exclusion criteria: A history of methamphetamine use within the last 3 months Alcohol dependence or benzodiazepines or hallucinogenic substances Diagnosis of methamphetamine-induced sustained psychosis

Design outcomes

Primary

Measure	Time frame
Psychosis leaderboard. Timepoint: The first day before the intervention and the fourth day after the intervention. Method of measurement: interview.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Bamani Glena Abadi

Kerman University of Medical Sciences

alibemani1355@gmail.com+98 34 3211 0408

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026